We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis.
- Authors
Deodhar, Atul; Machado, Pedro M; Mørup, Michael; Taieb, Vanessa; Willems, Damon; Orme, Michelle; Pritchett, David; Gensler, Lianne S
- Abstract
Objectives To compare the efficacy and safety of bimekizumab 160 mg every 4 weeks, a selective inhibitor of IL-17F and IL-17A, with those of biologic/targeted synthetic DMARDs (b/tsDMARDs) in non-radiographic axial SpA (nr-axSpA) and AS. Methods A systematic literature review identified randomized controlled trials until January 2023 for inclusion in Bayesian network meta-analyses (NMAs), including three b/tsDMARDs exposure networks: predominantly-naïve, naïve, and experienced. Outcomes were Assessment of SpondyloArthritis international Society (ASAS)20, ASAS40 and ASAS partial remission (PR) response rates at 12–16 weeks. A safety NMA investigated discontinuations due to any reason and serious adverse events at 12–16 weeks. Results The NMA included 36 trials. The predominantly-naïve network provided the most comprehensive results. In the predominantly-naïve nr-axSpA analysis, bimekizumab had significantly higher ASAS20 response rates vs secukinumab 150 mg [with loading dose (LD)/without LD], and comparable response rates vs other active comparators. In the predominantly-naïve AS analysis, bimekizumab had significantly higher ASAS40 response rates vs secukinumab 150 mg (without LD), significantly higher ASAS-PR response rates vs secukinumab 150 mg (with LD) and comparable response rates vs other active comparators. Bimekizumab demonstrated similar safety to that of other b/tsDMARDs. Conclusion Across ASAS outcomes, bimekizumab was comparable with most b/tsDMARDs, including ixekizumab, TNF inhibitors and upadacitinib, and achieved higher response rates vs secukinumab for some ASAS outcomes in predominantly b/tsDMARD-naïve nr-axSpA and AS patients at 12–16 weeks. In a pooled axSpA network, bimekizumab demonstrated comparable safety vs other b/tsDMARDs.
- Subjects
THERAPEUTIC use of monoclonal antibodies; PATIENT safety; RESEARCH funding; ANKYLOSIS; ANTIRHEUMATIC agents; META-analysis; TREATMENT effectiveness; MONOCLONAL antibodies; SYSTEMATIC reviews; DRUG efficacy; SPONDYLOARTHROPATHIES; COMPARATIVE studies
- Publication
Rheumatology, 2024, Vol 63, Issue 5, p1195
- ISSN
1462-0324
- Publication type
Article
- DOI
10.1093/rheumatology/kead598